Sangamo Therapeutics (SGMO) Projected to Post Earnings on Thursday

Sangamo Therapeutics (NASDAQ:SGMO) will likely be posting its Q1 2025 quarterly earnings results before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.12) per share and revenue of $7.90 million for the quarter.

Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings data on Monday, March 17th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.02). The company had revenue of $7.55 million for the quarter, compared to analysts’ expectations of $11.70 million. Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. On average, analysts expect Sangamo Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Sangamo Therapeutics Trading Down 1.1 %

Shares of SGMO stock opened at $0.72 on Tuesday. Sangamo Therapeutics has a 12-month low of $0.30 and a 12-month high of $3.18. The stock has a market capitalization of $165.02 million, a P/E ratio of -0.96 and a beta of 1.46. The firm’s 50 day moving average is $0.80 and its 200 day moving average is $1.38.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Sangamo Therapeutics in a research note on Monday, April 7th. Truist Financial lowered their target price on Sangamo Therapeutics from $7.00 to $5.00 and set a “buy” rating on the stock in a report on Thursday, January 23rd. Finally, Royal Bank of Canada restated a “sector perform” rating and set a $2.00 price target on shares of Sangamo Therapeutics in a research note on Tuesday, March 18th. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, Sangamo Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $5.17.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.